Tafazzin deficiency attenuates anti-cluster of differentiation 40 and interleukin-4 activation of mouse B lymphocytes.

Cell Tissue Res

Diabetes Research Envisioned and Accomplished in Manitoba (DREAM) Theme, Department of Pharmacology & Therapeutics, Rady Faculty of Health Sciences, Children's Hospital Research Institute of Manitoba, University of Manitoba, Winnipeg, Canada.

Published: December 2022

Barth syndrome (BTHS) is a rare X-linked genetic disease caused by mutations in TAFAZZIN. The tafazzin (Taz) protein is a cardiolipin remodeling enzyme required for maintaining mitochondrial function. Patients with BTHS exhibit impaired mitochondrial respiratory chain and metabolic function and are susceptible to serious infections. B lymphocytes (B cells) play a vital role in humoral immunity required to eradicate circulating antigens from pathogens. Intact mitochondrial respiration is required for proper B-cell function. We investigated whether Taz deficiency in mouse B cells altered their response to activation by anti-cluster of differentiation 40 (anti-CD40) + interleukin-4 (IL-4). B cells were isolated from 3-4-month-old wild type (WT) or tafazzin knockdown (TazKD) mice and were stimulated with anti-CD40 + IL-4 for 24 h and cellular bioenergetics, surface marker expression, proliferation, antibody production, and proteasome and immunoproteasome activities determined. TazKD B cells exhibited reduced mRNA expression of Taz, lowered levels of cardiolipin, and impairment in both oxidative phosphorylation and glycolysis compared to WT B cells. In addition, anti-CD40 + IL-4 stimulated TazKD B cells expressed lower levels of the immunogenic surface markers, cluster of differentiation 86 (CD86) and cluster of differentiation 69 (CD69), exhibited a lower proliferation rate, reduced production of immunoglobulin M and immunoglobulin G, and reduced proteasome and immunoproteasome proteolytic activities compared to WT B cells stimulated with anti-CD40 + IL-4. The results indicate that Taz is required to support T-cell-dependent signaling activation of mouse B cells.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00441-022-03692-zDOI Listing

Publication Analysis

Top Keywords

anti-cluster differentiation
8
activation mouse
8
cells
8
mouse cells
8
stimulated anti-cd40 + il-4
8
proteasome immunoproteasome
8
tazkd cells
8
compared cells
8
cluster differentiation
8
tafazzin
4

Similar Publications

Background: Tumor-selective oncolytic viral vectors are promising anticancer therapeutics; however, challenges with dosing and potency in advanced/metastatic cancers have limited efficacy and usage. NG-350A is a next-generation blood-stable adenoviral vector engineered to express an agonist anti-cluster of differentiation (CD)40 antibody without affecting tumor-selectivity and oncolytic potency.

Methods: Intravenous and intratumoral (IT) administration of NG-350A was assessed in a phase Ia/Ib study in patients with metastatic/advanced epithelial tumors (NCT03852511).

View Article and Find Full Text PDF
Article Synopsis
  • Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) have limited treatment options, prompting the investigation of magrolimab (M) combined with rituximab (R), and M combined with gemcitabine-oxaliplatin (M+R-GemOx) for long-term disease control.
  • In a study involving 132 patients, M+R achieved an objective response rate (ORR) of 24%, while M+R-GemOx showed a higher ORR of 52%, with notable complete response (CR) rates of 12% and 39%, respectively.
  • Both treatments were generally well tolerated, though common side effects included fatigue and anemia, with
View Article and Find Full Text PDF
Article Synopsis
  • R/R indolent non-Hodgkin lymphoma (iNHL) is often deemed incurable, but a phase 1b/2 study found that combining magrolimab (an anti-CD47 antibody) with rituximab (an anti-CD20 antibody) shows promising antitumor effects.
  • In this study, 46 patients were treated and showed a 52.2% overall response rate, with 30.4% achieving a complete response and median duration of response at 15.9 months.
  • Long-term follow-up (median 36.7 months) revealed no new toxicities or treatment-related deaths, indicating the combination's long-term safety and effectiveness, encouraging further research into CD
View Article and Find Full Text PDF

Suppressing anti-citrullinated protein antibody-induced osteoclastogenesis in rheumatoid arthritis using anti-CD64 and PAD-2 inhibitors.

Clin Exp Rheumatol

August 2024

Division of Rheumatology, Department of Internal Medicine, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Republic of Korea.

Objectives: To evaluate the role of Fcγ receptors (FcγR) and peptidyl arginine deiminase (PAD) in anti-citrullinated protein antibody (ACPA)-induced fibroblast-like synoviocytes (FLSs)-mediated osteoclastogenesis in patients with rheumatoid arthritis (RA).

Methods: FLSs and peripheral blood mononuclear cells were collected from patients with RA. We stimulated RA-FLS with ACPA (100 ng/ml) with and without anti-cluster of differentiation (CD)32a/CD64 (FcγRIIA/FcγRI) antibody and PAD-2/4 inhibitors.

View Article and Find Full Text PDF

Anti-cluster of differentiation (CD) 3 × α programmed death-ligand 1 (PD-L1) bispecific T-cell engager (BsTE)-bound T-cells (BsTE:T) are a promising new cancer treatment agent. However, the mechanisms of action of bispecific antibody-armed activated T-cells are poorly understood. Therefore, this study aimed to investigate the anti-tumor mechanism and efficacy of BsTE:T.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!